HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
2 BNMI - Biologie Neurovasculaire et Mitochondriale Intégrée
3 IRCCS - Istituto di Ricovero e Cura a Carattere Scientifico
4 UP13 - Université Paris 13
5 Hôpital Avicenne [AP-HP]
6 Vall d'Hebron University Hospital [Barcelona]
7 Sackler Faculty of Medicine
8 CHU Pitié-Salpêtrière [AP-HP]
9 UniBs - Università degli Studi di Brescia = University of Brescia
10 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
11 MSP - Mitochondrie, Stress oxydant et Protection musculaire
12 UNICAEN - Université de Caen Normandie
13 Hacettepe University = Hacettepe Üniversitesi
14 IRM - Immuno-Rhumatologie Moléculaire
15 Hôpital Saint-Joseph [Marseille]
16 Department of Obstetrics and Gynecology, I.M. Sechenow First Moscow State Medical University, Moscow, Russia.
17 ImmunoConcept - Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle
18 IRCCS - Istituti di Ricovero e Cura a Carattere Scientifico
19 Unipd - Università degli Studi di Padova = University of Padua
20 University of Medicine and Pharmacy, Luliu-Hatieganu
21 Hôpital Européen [Fondation Ambroise Paré - Marseille]
22 Maastricht University [Maastricht]
23 University of Alberta
24 Universitatea Babeş-Bolyai [Cluj-Napoca]
25 Centre Hospitalier du Mans
26 Ghent University Hospital
27 University of Belgrade [Belgrade]
28 Althaia Healthcare Network of Manresa, Barcelona
29 MITOVASC - MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale
30 CARFI - Cardiovascular Functions In Vitro
31 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
32 CRT - Centre de Recherche Translationnelle - Center for Translational Science
33 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
34 UNS - Université Nice Sophia Antipolis (1965 - 2019)
35 CRCNA - Centre de Recherche en Cancérologie Nantes-Angers
36 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
37 VRCM - Vascular research center of Marseille
38 C2VN - Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research
39 Department of Obstetrics and Gynecology, I.M. Sechenow First Moscow State Medical University, Moscow
40 IMVA - U1184 - Immunologie des Maladies Virales et Autoimmunes
41 Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
42 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
43 Hospital Carlos G. Durand
44 Hôpital Haut-Lévêque [CHU Bordeaux]
45 UMCG - University Medical Center Groningen [Groningen]
46 UMCU - University Medical Center [Utrecht]
47 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
48 CIC - Centre d'Investigation Clinique [Rennes]
49 Cellules Souches et Développement / Stem Cells and Development
50 Semmelweis University [Budapest]
51 TIMC-IMAG - Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525
52 Hospital de São João [Porto]
53 Hôpital La Rabta [Tunis]
54 Hôpital Lariboisière
55 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
56 Service de rhumatologie [Strasbourg]
57 UMPCD - University of Medicine and Pharmacy “Carol Davila”
58 CUHK - The Chinese University of Hong Kong [Hong Kong]
59 Diaverum Dialysis Center, Angers
60 ICAReB - Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources
61 Institut Arnault Tzanck
62 CRESIB - Barcelona Centre for International Health Research, Hospital Clinic
- Fonction : Auteur correspondant
- Fonction : Auteur
- PersonId : 774635
- IdRef : 184462436
- Fonction : Auteur
- PersonId : 767588
- ORCID : 0000-0002-5406-7716
- Fonction : Auteur
- PersonId : 735667
- IdHAL : laurent-arnaud
- ORCID : 0000-0002-4432-4205
- IdRef : 026691019
- Fonction : Auteur
- PersonId : 756121
- ORCID : 0000-0002-5374-3639
- Fonction : Auteur
- Fonction : Auteur
- PersonId : 182717
- IdHAL : celine-fassot
- ORCID : 0000-0003-0145-8411
- IdRef : 241982189
- Fonction : Auteur
- PersonId : 749483
- IdHAL : milena-hasan
- ORCID : 0000-0002-0879-7099
- Fonction : Auteur
- PersonId : 178861
- IdHAL : daniel-henrion
- ORCID : 0000-0003-1094-0285
- IdRef : 092696252
- Fonction : Auteur
- PersonId : 803126
- ORCID : 0000-0001-9315-1577
- IdRef : 118722352
- Fonction : Auteur
- PersonId : 756120
- ORCID : 0000-0002-4206-7399
- Fonction : Auteur
- PersonId : 738906
- IdHAL : laurent-loufrani
- ORCID : 0000-0003-3397-2335
- IdRef : 191329398
- Fonction : Auteur
- PersonId : 183399
- IdHAL : thierrymartin105
- ORCID : 0000-0001-8320-7055
- Fonction : Auteur
- PersonId : 740091
- IdHAL : muchardt
- ORCID : 0000-0003-0145-4023
- IdRef : 111170133
- Fonction : Auteur
- Fonction : Auteur
- PersonId : 1367614
- ORCID : 0000-0001-6494-5984
- Fonction : Auteur
- Fonction : Auteur
- PersonId : 948651
Résumé
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3].Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16].Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency.Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial.This trial consists in two parts: a retrospective and a prospective study.The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.